Skip to main content

Cluster analysis of longitudinal treatment patterns in patients newly diagnosed with systemic lupus erythematosus in the United States

Background

Treatments for systemic lupus erythematosus (SLE) include corticosteroids (CS), antimalarials, nonsteroidal anti-inflammatory drugs, cytotoxic agents, and immunosuppressive/immunomodulatory agents. We examined treatment patterns in newly diagnosed SLE patients from a multipayer US claims database.

Methods

This study (GSK HO-13-13054) retrospectively followed incident SLE patients' treatment for 4 years in the MarketScan commercial claims database. The earliest medical claim date with SLE diagnosis (ICD-9 code 710.0x; 1 January 2002 to 31 March 2008) was the index date. Patients were ≥18 years at index, had continuous medical and pharmacy benefits for 12 months pre index without SLE diagnosis and 48 months post index, with ≥1 SLE-related inpatient claim or ≥2 office or emergency room visits with SLE diagnosis ≥30 days apart within 12 months post index. A specialist must have made ≥1 SLE diagnosis at index or within 12 months post index. Results were stratified by provider type (primary care physician (PCP)/specialist). A disjoint k-means cluster analysis identified treatment pathways using annual prescription numbers for CS, hydroxychloroquine (HCQ), mycophenolate mofetil, azathioprine, and methotrexate as input variables.

Results

The study identified 2,086 newly diagnosed SLE patients (mean age: 47.2 years; female: 91%). In the 4 years post index, 1,031 (49.4%) patients were not actively treated (<0.05 prescriptions/year). Of the 219 (10.5%) patients who primarily received CS, 42 had persistently high numbers of prescriptions (~1/month), and 177 received 4.9 (mean) prescriptions in Year 1, decreasing in Years 2 to 4. Three subgroups emerged within the 606 (29.1%) patients who primarily received HCQ: persistent high number of prescriptions (~1/month), persistent moderate number of prescriptions (3.2 to 4.1/year), and poor adherence (Year 1, 8.7 prescriptions; Years 2 to 4, decreasing prescriptions). Both CS and HCQ were received by 138 (6.6%) patients; 56 had high numbers of prescriptions (Years 1 to 4); 82 showed progressively decreasing prescriptions. Fifty-four (2.6%) and 38 (1.8%) patients had moderate numbers of prescriptions for methotrexate (5.4 to 8.4/year) and azathioprine (5.7 to 7.5/year), respectively, with some CS and HCQ prescriptions. Treatment patterns differed in patients seen by specialists versus PCPs (P < 0.0001). Specialist-treated patients had a lower no-treatment rate than PCP-treated patients, and higher rates in active treatment clusters (Table 1).

Table 1 Longitudinal treatment patterns according to primary treatment by specialist or PCP

Conclusions

Treatment patterns were observed among SLE patients using medical resources. In the 4 years post diagnosis: ~50% of patients were not actively treated; 50% received CS, HCQ, and immunosuppressants with differing combinations, intensities, and adherence levels. Specialists provided more intensive treatment than PCPs.

Acknowledgements

Study and editorial support (Natasha Thomas, Fishawack Indicia Ltd) funded by GlaxoSmithKline.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hong Kan.

Additional information

Competing interests

CM, HK, JP, and SN are employees of and hold stock in GlaxoSmithKline. DJW is a consultant for GlaxoSmithKline.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kan, H., Nagar, S., Patel, J. et al. Cluster analysis of longitudinal treatment patterns in patients newly diagnosed with systemic lupus erythematosus in the United States. Arthritis Res Ther 16, A52 (2014). https://doi.org/10.1186/ar4668

Download citation

Keywords

  • Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus Patient
  • Mycophenolate Mofetil
  • Hydroxychloroquine
  • Treatment Pattern